Insulin detemir: from concept to clinical experience

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2006-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.7.3.325PMID 16448327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid-acting insulin secretagogues: a clinical need?

  2009cited by this paper
• Basal and 24-h C-peptide and insulin secretion rate in normal man

  2005cited by this paper
• Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

  2005influential reference
• Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

  2005cited by this paper
• Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

  2005influential reference
• A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

  2005influential reference
• Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

  2005influential reference
• A Comparison of Bedtime Insulin Glargine with Bedtime Neutral Protamine Hagedorn Insulin in Patients with Type 2 Diabetes: Subgroup Analysis of Patients Taking Once-Daily Insulin in a Multicenter, Randomized, Parallel Group Study

  2004cited by this paper
• Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

  2004influential reference
• Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with type 1 diabetes

  2004influential reference
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Insulin secretion in type 1 diabetes.

  2004cited by this paper
• Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

  2004influential reference
• Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

  2004cited by this paper
• Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

  2004cited by this paper
• The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

  2004influential reference
• Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

  2004influential reference
• Similarity of Insulin Detemir Pharmacokinetics, Safety, and Tolerability Profiles in Healthy Caucasian and Japanese American Subjects

  2004cited by this paper
• Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.

  2004cited by this paper
• The 12-Month Efficacy and Safety of Insulin Detemir and NPH Insulin in Basal-Bolus Therapy for the Treatment of Type 1 Diabetes

  2004influential reference
• A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes.

  2003cited by this paper
• Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.

  2003cited by this paper
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003influential reference
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

  2003cited by this paper
• Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.

  2003cited by this paper
• New insulins in the treatment of diabetes mellitus.

  2002influential reference
• Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion.

  2002cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes

  2002cited by this paper
• Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

  2002cited by this paper
• Variability of Insulin Absorption and Insulin Action

  2002cited by this paper
• Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake.

  2002cited by this paper
• Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

  2001influential reference
• Basal Insulin Glargine (HOE 901) versus NPH Insulin in Patients With Type 1 Diabetes on Multiple Daily Insulin Regimes

  2001cited by this paper
• Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.

  2001cited by this paper
• Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

  2001cited by this paper
• Insulin glargine.

  2000cited by this paper
• Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

  2000cited by this paper
• A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

  2000cited by this paper
• Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

  2000cited by this paper
• Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

  2000cited by this paper
• Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

  2000cited by this paper
• Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

  2000cited by this paper
• Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

  2000cited by this paper
• Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial

  2000cited by this paper
• Activation of hypothalamic insulin by serotonin is the primary event of the insulin-serotonin interaction involved in the control of feeding.

  2000cited by this paper
• Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.

  1999cited by this paper
• Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

  1999cited by this paper
• Insulin analogues and their potential in the management of diabetes mellitus

  1999cited by this paper
• Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

  1999cited by this paper
• Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Optimization of Evening Insulin Dose in Patients Using the Short-Acting Insulin Analog Lispro

  1998cited by this paper
• Increase in plasma leptin and Lep mRNA concentrations by food intake is dependent on insulin.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Optimal Provision of Daytime NPH Insulin in Patients Using the Insulin Analog Lispro

  1998cited by this paper
• Crystal structure of a prolonged-acting insulin with albumin-binding properties.

  1997cited by this paper
• Intensive insulin therapy in clinical practice

  1997cited by this paper
• Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment

  1997cited by this paper
• The Emotional, Social, and Behavioral Implications of Insulin-Induced Hypoglycemia.

  1997cited by this paper
• The Psychosocial Impact of Severe Hypoglycemic Episodes on Spouses of Patients With IDDM

  1997cited by this paper
• Novel forms of insulin delivery.

  1997cited by this paper
• Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue.

  1997cited by this paper
• Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.

  1996cited by this paper
• The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.

  1996cited by this paper
• Psychological factors in intensive management of insulin-dependent diabetes mellitus.

  1996cited by this paper
• Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

  1996cited by this paper
• Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.

  1995cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Hypoglycaemia, the most feared complication of insulin therapy.

  1994cited by this paper
• The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Morphology of Palpably Abnormal Injection Sites and Effects on Absorption of Isophane(NPH) Insulin

  1990cited by this paper
• Effects of chronic intrahypothalamic infusion of insulin on food intake and diurnal meal patterning in the rat.

  1990cited by this paper
• Monomeric Insulins and Their Experimental and Clinical Implications

  1990cited by this paper
• Double-Blind Crossover Trial of Isophane (NPH)- and Lente-Based Insulin Regimens

  1989cited by this paper
• Effect of Raising Injection-Site Skin Temperature on Isophane (NPH) Insulin Crystal Dissociation

  1989cited by this paper
• Monomeric insulins obtained by protein engineering and their medical implications

  1988cited by this paper
• Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.

  1988cited by this paper
• Continuous Subcutaneous Insulin Infusion Versus Injection Therapy: A Randomized Cross‐over Trial Under Usual Diabetic Clinic Conditions

  1987cited by this paper
• Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain.

  1987cited by this paper
• Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30.

  1987cited by this paper
• Landmark article Jan 18, 1936: Protamine insulinate. By H.C. Hagedorn, B.N. Jensen, N.B. Krarup, and I. Wodstrup.

  1984cited by this paper
• Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast.

  1983cited by this paper
• Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures

  1981cited by this paper
• Variation in125i-insulin absorption and blood glucose concentration

  1979cited by this paper
• Protamine Insulinate

  1937cited by this paper
• STUDIES ON INSULIN WITH PROTAMINE

  1936cited by this paper

• Temperature induces a shift from insulin dihexamer to hexamer in collective dynamics

  2025cites this paper
• BioJect: An in vitro platform to explore release dynamics of peptides in subcutaneous drug delivery.

  2025cites this paper
• Effect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1

  2025cites this paper
• Allosteric Residue Dynamics in Insulin: Temperature Induces Shift from Dihexamer to Hexamer Collective Motion

  2025cites this paper
• Diboronate-Modified Hyaluronic Acid for Glucose-Responsive Insulin Delivery.

  2025cites this paper
• Triple Calcium Binding Stoichiometry in the Monoclinic Crystal Form of Protracted Insulin

  2025cites this paper
• Engineering a Pathway to Glucose-Responsive Therapeutics.

  2024cites this paper
• Reductive amination of ω-conotoxin MVIIA: synthesis, determination of modification sites, and self-assembly

  2024cites this paper
• A phage-displayed disulfide constrained peptide discovery platform yields novel human plasma protein binders

  2024cites this paper
• Unraveling Light-Activated Insulin Action in Regulating Blood Glucose: New Photoactivatable Insight as a Novel Modality in Diabetes Management

  2024cites this paper
• Evolution of biosynthetic human insulin and its analogues for diabetes management.

  2024cites this paper
• Lipidization as a tool toward peptide therapeutics

  2023cites this paper
• Self-Assembly Nanostructure of Myristoylated ω-Conotoxin MVIIA Increases the Duration of Efficacy and Reduces Side Effects

  2023cites this paper
• Probing the Binding Mechanism of Acylated Peptides to Human Serum Albumin.

  2023cites this paper
• Role of Albumin as a Targeted Drug Carrier in the Management of Rheumatoid Arthritis: A Comprehensive Review.

  2023cites this paper
• Insulin–Dendrimer Nanocomplex for Multi‐Day Glucose‐Responsive Therapy in Mice and Swine

  2023cites this paper
• Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

  2022cites this paper
• Oromucosal delivery of macromolecules: Challenges and recent developments to improve bioavailability.

  2022cites this paper
• Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery.

  2021cites this paper
• "Clickable" Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals.

  2021cites this paper
• Albumin-based nanomaterials in drug delivery and biomedical applications

  2021cites this paper
• Fatty acylation enhances the cellular internalization and cytosolic distribution of a cystine-knot peptide

  2021cites this paper
• Zein-based nanomaterials in drug delivery and biomedical applications

  2021cites this paper
• Engineering biopharmaceutical formulations to improve diabetes management

  2021cites this paper
• Serum albumin: clinical significance of drug binding and development as drug delivery vehicle.

  2021cites this paper
• Synthesis and biological evaluation of S-lipidated lipopeptides of a connexin 43 channel inhibitory peptide.

  2020cites this paper
• Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance

  2020cites this paper
• Albumin-based drug designs for pharmacokinetic modulation

  2020cites this paper
• Cysteine protease inhibitors as novel therapeutics for the prevention of primary graft dysfunction after lung transplantation

  2020cites this paper
• Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study

  2020cites this paper
• Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.

  2020cites this paper
• The Discovery and Development of Liraglutide and Semaglutide

  2019cites this paper
• Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies.

  2019cites this paper
• Fusion with an albumin‐binding domain improves pharmacokinetics of an αvβ3‐integrin binding fibronectin scaffold protein

  2019cites this paper
• Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle

  2019cites this paper
• Möglichkeiten und Grenzen der aktuellen Insulintherapie

  2018cites this paper
• Advanced Genetic Fusion Techniques for Improving the Pharmacokinetic Properties of Biologics

  2018cites this paper
• Solid-Phase Thiol-Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist.

  2018cites this paper
• Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments.

  2017cites this paper
• Insulin Formulation Characterization—the Thioflavin T Assays

  2017cites this paper
• Möglichkeiten und Grenzen der aktuellen Insulintherapie

  2017cites this paper
• Chinese expert opinion on short-term intensive insulin therapy for type 2 diabetes

  2017cites this paper
• Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.

  2017cites this paper
• Peptide Lipidation – A Synthetic Strategy to Afford Peptide Based Therapeutics

  2017influential citation
• A comprehensive review of the neonatal Fc receptor and its application in drug delivery.

  2016cites this paper
• Science Journals — AAAS

  2016cites this paper
• Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

  2016cites this paper
• Albumin-based drug delivery: harnessing nature to cure disease

  2016cites this paper
• An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing.

  2016cites this paper
• Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.

  2016cites this paper
• Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics

  2015cites this paper
• Albumin: the next-generation delivery technology.

  2015cites this paper
• Albumin and its application in drug delivery

  2015cites this paper
• The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery.

  2015cites this paper
• Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.

  2015cites this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

  2014cites this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

  2014cites this paper
• New InsulinGlargine 300 Units / mL Versus Glargine 100 Units / mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin : Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial

  2014cites this paper
• Will the next generation of basal insulins offer clinical advantages?

  2014cites this paper
• In situ synthesized BSA capped gold nanoparticles: effective carrier of anticancer drug methotrexate to MCF-7 breast cancer cells.

  2014cites this paper
• Aufnahme von Albumin-Konjugaten in humane Tumor-Zelllinien

  2013cites this paper
• Albumin as a versatile platform for drug half-life extension.

  2013cites this paper
• Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulin.

  2013cites this paper
• Liporetro-D-peptides - a novel class of highly selective thrombin inhibitors.

  2012cites this paper
• Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered?

  2012cites this paper
• Defining the Role of Insulin Detemir in Basal Insulin Therapy

  2012cites this paper
• PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery.

  2012cites this paper
• Untersuchungen zur adipogenen Wirkung von Insulin Detemir auf 3T3-L1-Präadipozyten

  2012cites this paper
• Insulins: past, present, and future.

  2012cites this paper
• Hospital Strategies for Insulin Therapy with Rapid-Acting Insulin Analogs

  2011cites this paper
• Insulin Preparations with Prolonged Effect

  2011cites this paper
• Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods.

  2011cites this paper
• Pharmacokinetics of Immunoglobulin G and Serum Albumin: Impact of the Neonatal Fc Receptor on Drug Design

  2011cites this paper
• Basal Insulin: Physiology, Pharmacology, and Clinical Implications

  2011cites this paper
• Type 1 Diabetes Mellitus

  2011cites this paper
• Insulin detemir: A historical perspective on a modern basal insulin analogue.

  2010influential citation
• Long-acting insulin analogues: comparative characteristics of their structure, pharmacological properties, and potential for clinical application

  2010cites this paper
• How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

  2010cites this paper
• Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

  2010cites this paper
• Stability, liposome interaction, and in vivo pharmacology of ghrelin in liposomal suspensions.

  2010cites this paper
• Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

  2010cites this paper
• Nuevas insulinas. Actualización

  2009cites this paper
• Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal–bolus regimens: insights from the PREDICTIVE study

  2009cites this paper
• Translating clinical guidelines into clinical practice: role of the pharmacist in type 2 diabetes management.

  2009cites this paper
• Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study.

  2009cites this paper
• Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH.

  2009cites this paper
• Overview of insulin delivery pen devices.

  2009cites this paper
• Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE

  2009cites this paper
• The hospital pharmacist: an integral part of the hyperglycaemic management team

  2009cites this paper
• Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins

  2009cites this paper
• Initiating and Intensifying Insulin Therapy for Type 2 Diabetes: Why, When, and How

  2009cites this paper
• The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

  2009cites this paper
• engineering Basal Insulin—Clinical evidence Translating to Clinical Experience

  2009cites this paper
• Exploring The Quality-Of-Life Benefits With Insulin Analog Use

  2009cites this paper
• [Update on new insulins].

  2009cites this paper
• Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy

  2009cites this paper
• Implementing Treatment Guidelines for Type 2 Diabetes in Primary Care

  2009cites this paper
• Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.

  2009cites this paper
• Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

  2009cites this paper
• Long-Acting Insulin Analogs Versus Human Insulins

  2008cites this paper